Latest Insider Transactions at Regulus Therapeutics Inc. (RGLS)
This section provides a real-time view of insider transactions for Regulus Therapeutics Inc. (RGLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Regulus Therapeutics Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Regulus Therapeutics Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 25
2025
|
Stelios Papadopoulos |
SELL
Sale (or disposition) back to the issuer
|
Direct |
64,635
-100.0%
|
-
|
|
Jun 25
2025
|
Stelios Papadopoulos |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
976,253
-93.79%
|
-
|
|
Jun 25
2025
|
Pascale Witz |
SELL
Sale (or disposition) back to the issuer
|
Direct |
67,233
-100.0%
|
-
|
|
Jun 25
2025
|
William H Rastetter |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
57,292
-100.0%
|
-
|
|
Jun 25
2025
|
William H Rastetter |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
44,264
-43.59%
|
-
|
|
Jun 25
2025
|
Joseph P Hagan Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
571,558
-100.0%
|
-
|
|
Jun 25
2025
|
Christopher Ray Aker Sr. VP & General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
83,125
-100.0%
|
-
|
|
Jun 25
2025
|
Christopher Ray Aker Sr. VP & General Counsel |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
60,796
-42.24%
|
-
|
|
Jun 25
2025
|
Preston Klassen President & Head of R & D |
SELL
Sale (or disposition) back to the issuer
|
Direct |
115,555
-100.0%
|
-
|
|
Jun 25
2025
|
Hugh Rosen |
SELL
Sale (or disposition) back to the issuer
|
Direct |
57,292
-100.0%
|
-
|
|
Jun 25
2025
|
Hugh Rosen |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
6,979
-10.86%
|
-
|
|
Jun 25
2025
|
Kathryn J Collier |
SELL
Sale (or disposition) back to the issuer
|
Direct |
75,565
-100.0%
|
-
|
|
Jun 25
2025
|
Alice Shih Hou Huang |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
57,292
-100.0%
|
-
|
|
Jun 25
2025
|
Alice Shih Hou Huang |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
27,377
-32.33%
|
-
|
|
Jun 25
2025
|
Alice Shih Hou Huang |
SELL
Sale (or disposition) back to the issuer
|
Direct |
57,292
-100.0%
|
-
|
|
Jun 25
2025
|
Alice Shih Hou Huang |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,208
-8.33%
|
-
|
|
Jun 25
2025
|
Jason Raleigh Nunn |
SELL
Sale (or disposition) back to the issuer
|
Direct |
62,500
-100.0%
|
-
|
|
Jun 25
2025
|
David Baltimore |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
57,292
-100.0%
|
-
|
|
Jun 25
2025
|
David Baltimore |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
5,208
-8.33%
|
-
|
|
Jun 25
2025
|
David Baltimore |
SELL
Sale (or disposition) back to the issuer
|
Direct |
57,292
-100.0%
|
-
|
|
Jun 25
2025
|
David Baltimore |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
27,377
-32.33%
|
-
|
|
Jun 25
2025
|
Crispina Calsada Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
140,228
-100.0%
|
-
|
|
Jun 17
2025
|
Kathryn J Collier |
BUY
Exercise of conversion of derivative security
|
Direct |
4,929
+3.7%
|
$44,361
$9.35 P/Share
|
|
Jun 16
2025
|
Kathryn J Collier |
BUY
Exercise of conversion of derivative security
|
Direct |
1,396
+2.02%
|
$12,564
$9.9 P/Share
|
|
Jun 03
2025
|
Preston Klassen President & Head of R & D |
BUY
Open market or private purchase
|
Direct |
12,000
+19.98%
|
$84,000
$7.99 P/Share
|
|
Apr 30
2025
|
Jason Raleigh Nunn |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+50.0%
|
-
|
|
Apr 30
2025
|
William H Rastetter |
BUY
Grant, award, or other acquisition
|
Indirect |
62,500
+38.1%
|
-
|
|
Apr 30
2025
|
Hugh Rosen |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+49.3%
|
-
|
|
Apr 30
2025
|
Kathryn J Collier |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+47.44%
|
-
|
|
Apr 30
2025
|
Pascale Witz |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+48.18%
|
-
|
|
Apr 30
2025
|
Alice Shih Hou Huang |
BUY
Grant, award, or other acquisition
|
Indirect |
62,500
+42.47%
|
-
|
|
Apr 30
2025
|
Alice Shih Hou Huang |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+50.0%
|
-
|
|
Apr 30
2025
|
David Baltimore |
BUY
Grant, award, or other acquisition
|
Indirect |
62,500
+50.0%
|
-
|
|
Apr 30
2025
|
David Baltimore |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+42.47%
|
-
|
|
Apr 30
2025
|
Stelios Papadopoulos |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+5.66%
|
-
|
|
Jan 30
2025
|
David Baltimore |
BUY
Open market or private purchase
|
Direct |
19,610
+46.94%
|
$19,610
$1.06 P/Share
|
|
Jan 30
2025
|
Joseph P Hagan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+16.09%
|
$50,000
$1.09 P/Share
|
|
Jan 14
2025
|
Crispina Calsada Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,088
-10.06%
|
$5,088
$1.26 P/Share
|
|
Jan 14
2025
|
Joseph P Hagan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,764
-5.29%
|
$11,764
$1.26 P/Share
|
|
Jan 14
2025
|
Christopher Ray Aker Sr. VP & General Counsel |
SELL
Open market or private sale
|
Direct |
5,088
-9.31%
|
$5,088
$1.26 P/Share
|
|
Jan 13
2025
|
Preston Klassen President & Head of R & D |
SELL
Open market or private sale
|
Direct |
31,445
-46.59%
|
$31,445
$1.26 P/Share
|
|
Jan 13
2025
|
Crispina Calsada Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
38,716
-43.36%
|
$38,716
$1.26 P/Share
|
|
Jan 13
2025
|
Joseph P Hagan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
115,290
-34.12%
|
$115,290
$1.26 P/Share
|
|
Jan 13
2025
|
Christopher Ray Aker Sr. VP & General Counsel |
SELL
Open market or private sale
|
Direct |
38,547
-41.37%
|
$38,547
$1.26 P/Share
|
|
Jan 09
2025
|
Preston Klassen President & Head of R & D |
BUY
Grant, award, or other acquisition
|
Direct |
67,500
+40.38%
|
$67,500
$1.33 P/Share
|
|
Jan 09
2025
|
Christopher Ray Aker Sr. VP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
84,125
+31.31%
|
$84,125
$1.33 P/Share
|
|
Jan 09
2025
|
Crispina Calsada Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
83,500
+33.42%
|
$83,500
$1.33 P/Share
|
|
Jan 09
2025
|
Joseph P Hagan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
280,750
+29.87%
|
$280,750
$1.33 P/Share
|
|
Jul 25
2024
|
Kathryn J Collier |
BUY
Open market or private purchase
|
Direct |
4,000
+37.24%
|
$4,000
$1.82 P/Share
|
|
Mar 14
2024
|
Stelios Papadopoulos |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+20.35%
|
$250,000
$1.6 P/Share
|